Mike Cawthorne
Mike Cawthorne is Director of Metabolic Research at the Clore Laboratory, University of Buckingham, where he leads a group of 15 researchers seeking new molecular targets and evaluating pioneering therapies for obesity and type 2 diabetes. From 1968 to 1994, Mike was at Beecham and SmithKline Beecham latterly as Group Director for Diabetes and Obesity Research. Apart from leading the research team that discovered rosiglitazone, he led the biological research that identified the ?3-adrenoceptor as a potential molecular target for thermogenesis and type 2 diabetes. Mike has published more than 100 papers in peer reviewed journals, is a past Chairman of the Association for the Study of Obesity, was founding secretary of the International Association for the Study of Obesity and received the 2001 award for drug discovery from the Society of Medicines research.
Register for updates
Complete the registration form to be kept up-to-date with news from MKP.
Framework agreement signed for pioneering Infrastructure Tariff
A new agreement that is expected to raise more that £300 million to help pay for the growth of Milton Keynes has been signed.
Top government official visits Milton Keynes
Communities and Local Government Permanent Secretary, Peter Housden, recently visited Milton Keynes to see how growth is developing in the 'new city' and in particular those areas where MKP is responsible for project delivery.
Annual Review 2006
The MKPC Annual Review is designed to update you on our activities and to highlight some of the year’s major achievements.
